Cargando…
The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation
SIMPLE SUMMARY: Oncological follow-up after liver transplantation for cholangiocellular carcinoma must consider the risk of recurrence. Immunosuppressive medication with so-called mTOR inhibitors seems to have a tumor-suppressive effect, as improved survival has been shown under this medication for...
Autores principales: | Gül-Klein, Safak, Schmitz, Paulina, Schöning, Wenzel, Öllinger, Robert, Lurje, Georg, Jonas, Sven, Uluk, Deniz, Pelzer, Uwe, Tacke, Frank, Schmelzle, Moritz, Pratschke, Johann, Ossami Saidy, Ramin Raul, Eurich, Dennis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221145/ https://www.ncbi.nlm.nih.gov/pubmed/35740555 http://dx.doi.org/10.3390/cancers14122890 |
Ejemplares similares
-
Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma
por: Ossami Saidy, Ramin Raul, et al.
Publicado: (2021) -
A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation
por: Ossami Saidy, Ramin Raul, et al.
Publicado: (2022) -
Reducing Immunosuppression in Patients with De Novo Lung Carcinoma after Liver Transplantation Could Significantly Prolong Survival
por: Pesthy, Sina, et al.
Publicado: (2022) -
How to Estimate the Probability of Tolerance Long-Term in Liver Transplant Recipients
por: Eurich, Dennis, et al.
Publicado: (2023) -
Long-Term Outcome after Liver Transplantation for Progressive Familial Intrahepatic Cholestasis
por: Gül-Klein, Safak, et al.
Publicado: (2021)